<DOC>
	<DOCNO>NCT00184626</DOCNO>
	<brief_summary>This trial conduct Asia . The aim trial compare glycaemic control Insulin glargine versus Biphasic Insulin Aspart 30/70 Biphasic Insulin Aspart 30/70 combination metformin subject Type 2 Diabetes .</brief_summary>
	<brief_title>Comparison Insulin Glargine Versus Biphasic Insulin Aspart 30/70 Biphasic Insulin Aspart 30/70 Combination With Metformin Subjects With Type 2 Diabetes .</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Insulin degludec , insulin aspart drug combination</mesh_term>
	<mesh_term>Insulin aspart , insulin aspart protamine drug combination 30:70</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<mesh_term>Biphasic Insulins</mesh_term>
	<mesh_term>Insulin Aspart</mesh_term>
	<mesh_term>Insulin , Long-Acting</mesh_term>
	<mesh_term>Insulin Glargine</mesh_term>
	<mesh_term>Insulin , Isophane</mesh_term>
	<criteria>Type 2 diabetes Body mass index equal lesser 35.0 kg/m2 Currently treat oral hypoglycaemic drug Known hypoglycaemia unawareness recurrent major hypoglycaemia judge Investigator Any condition Investigator and/or Sponsor feel would interfere trial participation evaluation result</criteria>
	<gender>All</gender>
	<minimum_age>35 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>